000182185 001__ 182185
000182185 005__ 20240229145713.0
000182185 0247_ $$2doi$$a10.3389/fimmu.2022.1010790
000182185 0247_ $$2pmid$$apmid:36263027
000182185 0247_ $$2pmc$$apmc:PMC9574214
000182185 0247_ $$2altmetric$$aaltmetric:136725314
000182185 037__ $$aDKFZ-2022-02487
000182185 041__ $$aEnglish
000182185 082__ $$a610
000182185 1001_ $$0P:(DE-He78)bc487db59becdf534f61e0fb31bc801d$$aAhmels, Melinda$$b0$$eFirst author$$udkfz
000182185 245__ $$aNext generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
000182185 260__ $$aLausanne$$bFrontiers Media$$c2022
000182185 3367_ $$2DRIVER$$aarticle
000182185 3367_ $$2DataCite$$aOutput Types/Journal article
000182185 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1666356138_20556
000182185 3367_ $$2BibTeX$$aARTICLE
000182185 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182185 3367_ $$00$$2EndNote$$aJournal Article
000182185 500__ $$a#EA:F030#EA:F035#LA:F030#
000182185 520__ $$aLicensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine. Further, their utility in protection against cutaneous HPV types, of which some contribute to non-melanoma skin cancer (NMSC) development, is rather low. Next generation vaccines achieve broadly cross-protective immunity against highly conserved sequences of L2. In this exploratory study, we tested two novel HPV vaccine candidates, HPV16 RG1-VLP and CUT-PANHPVAX, in the preclinical natural infection model Mastomys coucha. After immunization with either vaccines, a mock control or MnPV L1-VLPs, the animals were experimentally infected and monitored. Besides vaccine-specific seroconversion against HPV L2 peptides, the animals also developed cross-reactive antibodies against the cutaneous Mastomys natalensis papillomavirus (MnPV) L2, which were cross-neutralizing MnPV pseudovirions in vitro. Further, both L2-based vaccines also conferred in vivo protection as the viral loads in plucked hair after experimental infection were lower compared to mock-vaccinated control animals. Importantly, the formation of neutralizing antibodies, whether directed against L1-VLPs or L2, was able to prevent skin tumor formation and even microscopical signs of MnPV infection in the skin. For the first time, our study shows the proof-of-principle of next generation L2-based vaccines even across different PV genera in an infection animal model with its genuine PV. It provides fundamental insights into the humoral immunity elicited by L2-based vaccines against PV-induced skin tumors, with important implications to the design of next generation HPV vaccines.
000182185 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182185 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182185 650_7 $$2Other$$aL2-based vaccine
000182185 650_7 $$2Other$$aMastomys coucha
000182185 650_7 $$2Other$$aanimal model
000182185 650_7 $$2Other$$across-protection
000182185 650_7 $$2Other$$acutaneous HPV
000182185 650_7 $$2Other$$anext generation vaccine
000182185 650_7 $$2Other$$askin tumor formation
000182185 650_7 $$2Other$$askin tumors
000182185 650_7 $$2NLM Chemicals$$aPapillomavirus Vaccines
000182185 650_7 $$2NLM Chemicals$$aOncogene Proteins, Viral
000182185 650_7 $$2NLM Chemicals$$aVaccines, Virus-Like Particle
000182185 650_7 $$2NLM Chemicals$$aCapsid Proteins
000182185 650_7 $$2NLM Chemicals$$aAntibodies, Neutralizing
000182185 650_7 $$2NLM Chemicals$$aPeptides
000182185 650_2 $$2MeSH$$aMice
000182185 650_2 $$2MeSH$$aAnimals
000182185 650_2 $$2MeSH$$aHumans
000182185 650_2 $$2MeSH$$aPapillomavirus Vaccines
000182185 650_2 $$2MeSH$$aPapillomavirus Infections
000182185 650_2 $$2MeSH$$aOncogene Proteins, Viral
000182185 650_2 $$2MeSH$$aVaccines, Virus-Like Particle
000182185 650_2 $$2MeSH$$aNeutralization Tests
000182185 650_2 $$2MeSH$$aCapsid Proteins
000182185 650_2 $$2MeSH$$aMice, Inbred BALB C
000182185 650_2 $$2MeSH$$aPapillomaviridae
000182185 650_2 $$2MeSH$$aAntibodies, Neutralizing
000182185 650_2 $$2MeSH$$aNeoplasms
000182185 650_2 $$2MeSH$$aPeptides
000182185 7001_ $$0P:(DE-HGF)0$$aMariz, Filipe C$$b1$$eFirst author
000182185 7001_ $$0P:(DE-He78)810ef819c7d86928b119192db5730fc7$$aBraspenning-Wesch, Ilona$$b2$$udkfz
000182185 7001_ $$0P:(DE-He78)fd869847d6731bf306dce72ed1ef343b$$aStephan, Sonja$$b3$$udkfz
000182185 7001_ $$aHuber, Bettina$$b4
000182185 7001_ $$0P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748$$aSchmidt, Gabriele$$b5$$udkfz
000182185 7001_ $$0P:(DE-He78)aa2868b980249801b3207f4fbf65660b$$aCao, Rui$$b6
000182185 7001_ $$0P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aMüller, Martin$$b7$$udkfz
000182185 7001_ $$aKirnbauer, Reinhard$$b8
000182185 7001_ $$0P:(DE-He78)97f27961503f8b3233697cbad1bbed4e$$aRösl, Frank$$b9$$udkfz
000182185 7001_ $$0P:(DE-He78)93b84588571c05b85df1c0916f740e98$$aHasche, Daniel$$b10$$eLast author$$udkfz
000182185 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2022.1010790$$gVol. 13, p. 1010790$$p1010790$$tFrontiers in immunology$$v13$$x1664-3224$$y2022
000182185 909CO $$ooai:inrepo02.dkfz.de:182185$$pVDB
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bc487db59becdf534f61e0fb31bc801d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)810ef819c7d86928b119192db5730fc7$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd869847d6731bf306dce72ed1ef343b$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aa2868b980249801b3207f4fbf65660b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97f27961503f8b3233697cbad1bbed4e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000182185 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)93b84588571c05b85df1c0916f740e98$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000182185 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182185 9141_ $$y2022
000182185 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-29
000182185 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000182185 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000182185 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000182185 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000182185 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2021$$d2022-11-23
000182185 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000182185 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000182185 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:28:02Z
000182185 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:28:02Z
000182185 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T10:28:02Z
000182185 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000182185 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000182185 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2021$$d2022-11-23
000182185 9202_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000182185 9201_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000182185 9201_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x1
000182185 9201_ $$0I:(DE-He78)W210-20160331$$kW210$$lLichtmikroskopie$$x2
000182185 9200_ $$0I:(DE-He78)F030-20160331$$kF030$$lF030 Virale Transformationsmechanismen$$x0
000182185 9200_ $$0I:(DE-He78)F035-20160331$$kF035$$lF035 Tumorvirus-spez. Vakzinierungsstrategie$$x1
000182185 980__ $$ajournal
000182185 980__ $$aVDB
000182185 980__ $$aI:(DE-He78)F030-20160331
000182185 980__ $$aI:(DE-He78)F035-20160331
000182185 980__ $$aI:(DE-He78)W210-20160331
000182185 980__ $$aUNRESTRICTED